Comparative Pharmacology
Head-to-head clinical analysis: DILACOR XR versus DYNACIRC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILACOR XR versus DYNACIRC.
DILACOR XR vs DYNACIRC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary and systemic arteries, decreased myocardial contractility, and reduced sinoatrial and atrioventricular conduction velocity.
Dynacirc (isradipine) is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance, thereby lowering blood pressure.
180 to 240 mg orally once daily, administered on an empty stomach; maximum dose 480 mg once daily.
2.5-10 mg orally once daily; titrate based on response. Maximum 20 mg/day.
None Documented
None Documented
Terminal half-life: 6-12 hours (prolonged in elderly, hepatic impairment, or with CYP3A4 inhibitors)
Terminal elimination half-life is 7-8 hours. In elderly patients or those with hepatic impairment, half-life may be prolonged up to 14 hours, necessitating dose adjustment.
Renal (70% as metabolites, 3-4% as unchanged drug); biliary/fecal (25-30%)
Primarily hepatic metabolism (CYP3A4) with <1% excreted unchanged in urine; approximately 60% of metabolites are excreted in feces via bile, and 35% in urine.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker